What common biomarkers characterize a triple-negative profile in breast cancer?

I Kallel; M Rebaï; A Khabir; A Rebaï

doi:10.1016/j.patbio.2015.07.005

What common biomarkers characterize a triple-negative profile in breast cancer?

Pathol Biol (Paris). 2015 Sep;63(4-5):224-9. doi: 10.1016/j.patbio.2015.07.005. Epub 2015 Aug 20.

Authors

I Kallel¹, M Rebaï², A Khabir³, A Rebaï⁴

Affiliations

¹ Molecular and Cellular Diagnosis Processes, Centre of Biotechnology of Sfax, University of Sfax, Route Sidi Mansour, Po Box 1177, 3018 Sfax, Tunisia; Department of Pathology, Habib Bourguiba hospital, Sfax, Tunisia.
² Molecular and Cellular Diagnosis Processes, Centre of Biotechnology of Sfax, University of Sfax, Route Sidi Mansour, Po Box 1177, 3018 Sfax, Tunisia.
³ Department of Pathology, Habib Bourguiba hospital, Sfax, Tunisia.
⁴ Molecular and Cellular Diagnosis Processes, Centre of Biotechnology of Sfax, University of Sfax, Route Sidi Mansour, Po Box 1177, 3018 Sfax, Tunisia. Electronic address: ahmed.rebai@cbs.rnrt.tn.

PMID: 26300241
DOI: 10.1016/j.patbio.2015.07.005

Abstract

Triple-negative breast cancers are not a homogeneous subgroup. There is substantial intra-subgroup diversity in tumor biology, prognosis and treatment sensitivity. Then, these triple-negative phenotype (TNP) groups, having specific features, can be again divided into subclasses based on an added immunohistochemical markers. The challenge in treating TNP breast cancers is that they are not responsive to antiestrogens or trastuzumab secondary to negative receptor status, and as a result have a poor prognosis. Therefore, the presence or absence of supplementary markers could help predict which therapies are best suited for patients based on the pattern that their disease markers show. In this review, we will recapitulate the major supplementary biomarkers related to triple-negative breast cancer, which could give new therapeutic options.

Keywords: Biomarkers; Biomarqueurs; Breast cancer; Cancer du sein; Profil triple négatif; Prognosis; Pronostic; Triple-negative profile.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use
BRCA1 Protein / analysis
Biomarkers, Tumor / analysis*
Carcinoma, Ductal, Breast / chemistry*
Carcinoma, Ductal, Breast / drug therapy
Carcinoma, Ductal, Breast / ethnology
Carcinoma, Lobular / chemistry*
Carcinoma, Lobular / drug therapy
Carcinoma, Lobular / ethnology
Cyclin-Dependent Kinase Inhibitor p16 / analysis
ErbB Receptors / analysis
Ethnicity / statistics & numerical data
Female
Genes, BRCA1
Genes, erbB-1
Genes, p53
Humans
Hyaluronan Receptors / analysis
Molecular Targeted Therapy
Neoplasm Proteins / analysis*
Proto-Oncogene Proteins c-bcl-2 / analysis
Receptors, Androgen / analysis
Sensitivity and Specificity
Triple Negative Breast Neoplasms / chemistry*
Triple Negative Breast Neoplasms / classification
Triple Negative Breast Neoplasms / drug therapy
Triple Negative Breast Neoplasms / ethnology
Tumor Suppressor Protein p53 / analysis

Substances

Antineoplastic Agents
BRCA1 Protein
Biomarkers, Tumor
CD44 protein, human
Cyclin-Dependent Kinase Inhibitor p16
Hyaluronan Receptors
Neoplasm Proteins
Proto-Oncogene Proteins c-bcl-2
Receptors, Androgen
TP53 protein, human
Tumor Suppressor Protein p53
EGFR protein, human
ErbB Receptors